Drug intelligence / Profile preview

ABCL385

Development stage: Preclinical
Lead developer: AbCellera Biologics
Modality: Antibody-Based Therapeutics

Overview

ABCL385 is an investigational antibody drug candidate being developed by AbCellera. Announced in November 2026 alongside the company's Q3 2026 financial results, ABCL385 is being developed for an undisclosed indication in oncology. The program is currently in IND-enabling activities, and AbCellera does not expect to disclose further details about the candidate until it enters clinical development.

Beyond the preview

Go deeper on ABCL385.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABCL385.

Work on ABCL385? Claim this page to correct or add information. Claim this page